Hosted on MSN1mon
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency saysMedicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...
Medicare may cover Zepbound for people with moderate to severe ... Zepbound is a prescription-only weight loss drug manufactured by Eli Lilly. People prescribed this medication inject themselves ...
Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli Lilly, directly. Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP ...
10h
Hosted on MSNEli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
(Reuters) - Eli Lilly investors and analysts said ... The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare, now that the U.S. government health ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue ... yet competition, Medicare pricing, and valuation temper long-term horizons.
Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...
In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results